More than 88% of people in the Wegovy study reached healthy liver fat levels, says Novo.

NVO · Novo Nordisk A/S

The AI's read

These results give Novo Nordisk more evidence that Wegovy can lower liver fat, supporting its work on fatty liver disease. The MRI finding came from only 55 people, and most had little risk of advanced liver disease. The 7.2 mg dose is not being studied as a treatment for this condition, so the result does not establish its use at that dose.